Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.42 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | SCARB1 | Q8WTV0 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7187595 | 0.72 | CRHR1 (0.41) | ARCYP11B2CYP11B1TRPV4CRHR1 | |
| SCHEMBL7604551 | 0.70 | TRPV4 (0.56) | ARNSD2TRPV4 | |
| SCHEMBL5100862 | 0.68 | CRHR1 (0.37) | ARCYP11B2CYP11B1TRPV4SCARB1 | |
| SCHEMBL5104170 | 0.68 | CRHR1 (0.39) | ARCYP11B2CYP11B1TRPV4CRHR1 | |
| SCHEMBL6940971 | 0.67 | ALDH1A1 (0.39) | CREBBP | |
| SCHEMBL28668535 | 0.65 | KIF11 (0.57) | ARNSD2CYP11B2TRPV4 | |
| SCHEMBL250179 | 0.64 | AR (0.46) | ARNSD2CYP11B2CYP11B1TRPV4 | |
| SCHEMBL409405 | 0.64 | TRPV4 (0.53) | ARTRPV4 | |
| SCHEMBL3532873 | 0.63 | NOTUM (0.48) | ARTRPV4 | |
| SCHEMBL15730331 | 0.63 | LMNA (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1370540-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-17 | — | — | EP | disclosed |
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-05 | — | — | US | disclosed |
| WO-2002072558-A1 | ANTI-THROMBOTIC CARBOXYLIC ACID AMIDES, THE PRODUCTION THEREOF AND USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183519-A1 | Antithrombotic carboxylic acid amides | SERPINC1, TFPI, F2 | AR 3011/4885NSD2 2110/4885CYP11B2 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.